Rising freshman studying Community Health (Public) and Economics. Interested in all things tech software, the cloud, and biotech. Not providing professional investment advice. I may have positions in stocks that I write about.
Editor for The Biotech Forum (www.biotechforumsa.com), the #2 subscribed to Marketplace investment service offered through SeekingAlpha. Top 5% ranked analyst (TipRanks) 2013 through first half of 2015. Daily contributor for Real Money Pro. Hedge fund manager from 2008 to 2011. Previously technology executive at Fortune 100 firm for a decade. For Free weekly investment reports on small, attractive biotech stocks just register for free @ bretjenseninvests.com
I am an individual investor who has been actively involved in the healthcare and biotechnology space for over 15 years. I hold a PhD in the biomedical sciences and have worked in both large pharmaceutical and small biotech companies. I make investments based on the fundamentals of a company and if I believe they have a superior technology or products compared to the competition. I'm an investor who believes patience pays off.
Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
I am a retired global analyst, currently busy in investing and writing articles about stocks at several investing publications and websites. I have also developed strategies for creating winning portfolios according to specific formulas.
In January 2015, I was ranked among the world’s top 10 financial bloggers according to TipRanks, which holds financial experts accountable for their recommendations by disclosing their stock ratings since 2009:
Steven currently focuses his analyses primarily on the valuation of smaller biotechs (100MM to 1 BB market cap) and utilizes all sources of information, including conversations with management, peer-reviewed publications, SEC filings, and all available primary and secondary research.
Steven is currently a consultant for a New York based life science focused consultancy, and brings a strong scientific and financial background to his current position.
Previously, Steven earned a Ph.D. from the Scripps Research Institute and an M.A. from Columbia University, with extensive work in the field of synthetic and medicinal chemistry, publishing several papers in prestigious peer-reviewed journals. He is also pursuing the CFA designation, and has completed exam level 2.
Please email me with any questions, comments, and investment ideas. (stevenb29 at gmail.com)
Rob Goldman has over 20 years of investment and company research experience as a senior research analyst and as a portfolio and mutual fund manager. As the founder of Goldman Small Cap Research, Rob's routinely writes about small cap and micro cap companies. During his tenure as a sell-side analyst, Rob was a senior member of Piper Jaffray's Technology and Communications teams. Prior to joining Piper, Rob led Josephthal & Co.'s Washington-based Emerging Growth Research Group. In addition to his sell-side experience Rob served as Chief Investment Officer of a boutique investment management firm and Blue and White Investment Management, where he managed Small Cap Growth portfolios and The Blue and White Fund.
In addition to being a lawyer with a specific interest in securities and compliance law, Omnivestor has been an avid investor for the past ten years, specializing in small cap stocks undergoing special situations. Omnivestor is also currently part of the management team at a small boutique equity research firm.
Omnivestor lives on the East coast.
Disclosure : I am not a stockbroker or financial adviser. I am an investor making researched observations for the purpose of discussion and open communication and analysis of companies and stocks. All articles are my opinion only and are not suggestions to buy or sell any equity, bond, option or other financial instrument.
Author of the critically acclaimed book, "Taking Charge With Value Investing (McGraw-Hill, 2013)" and the premium subscription service "Tipping The Scale" (as seen below). An analyst that ranks in the top 4% on both tipranks.com and Motley Fool CAPS for stock picking performance.
Tipping the Scale members gain access to the TTS Portfolio Tracker. Here, members see what I am buying and selling the minute it happens, along with what I have owned, bought, and sold historically. These are just a few of the features on the TTS Portfolio Tracker.
Tipping The Scale is an equity research platform that uses a numeric scale instead of the traditional "Buy, Hold, Sell" to identify the best investment opportunities in the market. Stock coverage is determined by market catalyst, and every company goes through a vigorous test in 10 different categories. The higher the total score, the bigger the upside. In addition, Tipping the Scale also provides a number of portfolio strategies to hedge the volatility of the market and protect from downside.
Check out my instablog for more information on the popular research service Tipping the Scale, including performance information, benefits, and how it all works.
Long time biotech and tech investor who enjoys discussing stocks, options, and sharing ideas freely.
Investors buy or sell at their own risk. All my articles strictly represent an 'opinion' and in no-way should be construed as individual investor advice.
PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our Editorial Team is comprised of individuals with a strong background in science, medicine and the business of successfully commercializing therapeutics, medical devices, diagnostics and healthcare services. Our ultimate objective is to leverage the knowledge, experience, and relationships of our contributors to introduce our subscribers to profitable long and short investment opportunities in the healthcare sector.
Successfully trading, and investing in emerging growth healthcare companies is a difficult task. Over 90% of drugs never make it out of the clinic. Huge capital requirements along the way result in highly dilutive equity financings often done on the backs of retail investors. At PropThink, we believe that due diligence is the key to success in this industry. We leverage a combined 50 years of experience in science, medicine, legal, regulatory affairs, finance, and operational industry experience to analyze companies at a highly technical level. This detailed analysis and due diligence process defines our editorial strategy and provides our subscribers a high level of confidence in our research. Our focus is on identifying and analyzing technically-complicated companies and equities that are grossly over or under-valued.
Visit PropThink.com to see all of our coverage and research, and subscribe to our free newsletter to receive reports, articles, and trading alerts.
Jonathan Moreland is the founder and Director of Research at InsiderInsights.com, which produces the weekly InsiderInsights Newsletter, and offers institutional strength, real-time insider data and analytics via a subscription Data Module and APIs. He is also principal of Insider Asset Management llc, a registered investment advisor in New York State, and a past contributor to TheStreet.com, Minyanville, and other financial outlets.
A fundamental analyst with an MBA in finance, Mr. Moreland identified insider data over 25 years ago as an excellent first screen to determine where to focus his research efforts. He is quoted frequently in the media for his insider analysis, and stock recommendations stemming from it. He is also author of Profit From Legal Insider Trading (Dearborn 2001), and has a new book due out with Wiley.
Mr. Moreland is currently on a mission to get investors to expect more from insider data than the commodity feeds they rely on from their Bloomberg terminals, Yahoo!Finance, and other financial websites.
Bookmark QTR's new blog, where exclusive (and always FREE) content will be available: http://www.quoththeravenresearch.com
Visit QTR and check out trading ideas, commentary, and me arguing with idiots on Twitter: http://www.twitter.com/quoththeravensa
QTR's ARTICLES ARE BOUND BY SA'S CONTRIBUTOR POLICY IN ADDITION TO THIS ENTIRE LENGTHY, YET EXTREMELY PERTINENT ADD ON DISCLOSURE, WHICH SERVES AS BOTH A STANDALONE DISCLOSURE AND AN AMENDMENT TO ANY AND ALL DISCLOSURES ALREADY PRESIDING OVER SEEKING ALPHA:
Quoth the Raven's ("QTR") articles are the sole product of QTR and his personal, individual opinions. These articles are not associated with, in any way, the opinions, strategies, or works of QTR's employer, associates, or entities in any way otherwise related to QTR.
(i.e. This are solely my personal thoughts and opinions)
You agree that by reading Quoth the Raven's articles, you are acting at your OWN RISK. In NO EVENT should QTR be liable for any direct or indirect trading losses caused by any information contained in QTR's articles, StockTalks, or other internet-based dissemination methods. Information in QTR's articles are not an offer to sell or a solicitation of an offer to buy any security, nor shall any security be offered or sold to any person, in any jurisdiction in which such offer would be unlawful under the securities laws of such jurisdiction. QTR is not suggesting the transacting of any financial instruments and QTR suggests consulting your personal financial adviser with regards to any such transactions.
QTR makes no representations, and specifically disclaims all warranties, express, implied, or statutory, regarding the accuracy, timeliness, or completeness of any material contained in this site. Again, you should seek the advice of your personal financial adviser or a security professional regarding your stock transactions.
QTR does not, in any way, guarantee that he is providing all of the information that may be available on any topic written. QTR recommends, again, that you do your own due diligence and consult a registered financial adviser before buying or selling any security.
QTR most always holds a position in any of the securities profiled in his pieces and he constructs his SA disclosures in accordance with SA's Contributor Policy, to the best of his knowledge in order to maintain transparency and also to uphold and respect pertinent securities laws. QTR may or may not report when a position is initiated or covered. Each investor must make that decision based on his/her judgment of the market.
I am not a stockbroker or financial adviser. I am a casual investor making casual observations for the purpose of discussion and open communication and analysis of companies and stocks. All articles are my opinion only and are not suggestions to buy or sell any equity, bond, option or other financial instrument. QTR may have long or short positions in any tickers mentioned at any time and reserves the right to open, close, or modify positions at all time without notice. My conclusions are the result of my personal due diligence and have been wrong in the past. There are tons of unqualified people out there offering up financial advice and its your responsibility to sort through the BS. You don't hit the button to fill my orders and I don't hit yours, so no whining or praising over stocks covered by me.
Follow QTR on Twitter: https://twitter.com/QuoththeRavenSA
View QTR's Stock Picking Performance for every article at TipRanks:
I am a small-time writer/blogger who dreams big and enjoys researching and writing about biotechs and pharmaceuticals. My work experiences include food safety, water quality, pesticides, food additives, paints, plastics and pharmaceutical precursors. My focus as of late has been researching the treatment options for many cancers and prevention of their recurrence. Additional recent research has been in the stem cell field, an exciting field in its infancy but now becoming a teenager! My ongoing goal for investors is attempting to find under-the-radar or oversold pharmaceuticals or biotechs for investment potential.
I research early (micro cap) and mid phase publicly traded companies in the Biotechnology and Medical Device sectors that are harder to at times find information on for investors. I believe that these companies, although potentially more volatile than their larger cap retail counterparts, hold great value. With a clear understanding of where their product is positioned in the market, the capitalization and the team, these smaller companies can hold incredible value over the long term.
I have a varied background in both business and in the technical sector. Currently, I also am a co founder of BCN Biosciences in Pasadena CA, a privately held biotechnology company in addition to holding a research faculty position at the University of California Los Angeles Department of Radiation Oncology.
As an avid stock trader I am always searching for new opportunities. I utilize a very research heavy approach in my strategy that has done quite well for me over the years. I have earned a degree in Physics and an MBA in Finance. Although my educational background is an unconventional pairing, both have served me well. I am currently a consultant that specializes in small business development.
Theodore J. Cohen, Ph.D., a research scientist, has been an investor for more than 50 years. Since 1980, he has focused his attention on investment research and investigative analyses of companies developing therapeutic drugs in the biotech sector. Dr. Cohen is a frequent contributor of Guest Opinions (op-ed pieces) to the Bucks County (PA) Courier Times (circulation: 80,000), where, since 2007, he has addressed such varied subjects as the conflicts of interest (COIs) associated with two members of the Provenge advisory committee (AC); the U.S. Senate’s Durbin Amendment, to tighten COI reviews of FDA AC members; and naked short selling. Cohen is the author of the award-winning novels Death by Wall Street: Rampage of the Bulls (AuthorHouse, 2010) and House of Cards: Dead Men Tell No Tales (Outskirts Press, 2011), which were inspired by real events. The books are available from Amazon.com, B&N, and 26,000 online bookstores worldwide. For details, see http://www.theodore-cohen-novels.com.
Alexander Shadunsky began his career in business at a young age, when he became a part of the family newspaper business. After a brief stint in retail, he developed an interest in value investing and has been uncovering undervalued opportunities ever since. He is a regular reader of Seeking Alpha, Value Investor’s Club, and SEC documents.
Currently, Mr. Shadunsky is a small business consultant. He has spent time working on a wide variety of projects including business and equity valuations, corporate finance, business process automation, corporate communications, and strategic branding and positioning.
Mr. Shadunsky earned a bachelor’s degree in Finance from the Rochester Institute of Technology and has studied business at Indiana University as well. Previously, Mr. Shadunsky worked as an equity analyst at Briefing.com where he covered biotechnology and pharmaceutical stocks. He also spent time with Xerox and Merrill Lynch. He is fluent in Russian.
He can be contacted at alexs85(at)gmail.com.
I am a personal investor and an attorney. I have extensive experience in the consumer credit arena as well as commercial real estate as an investor and a lender. I co-manage a commercial, hard money mortgage fund and also have experience with the Food, Drug & Cosmetic Act.
The enormous advancement in the biological sciences that is taking place has begun to change the traditional way of practicing medicine. Far-reaching biological products are being approved and news about breakthroughs are occupying the media headlines. However, selecting the biotechnology firms for investment requires not only an understanding of the company's finances, but also deep knowledge of the company's potential and the potential and scientific validity of it's products and technologies.
Our Mission is evaluating biotechnology companies, their products, their technologies, scientists, managements, as well as their finances. Our goal is to impart our readers with the knowledge and insight so that they may have a heightened understanding and appreciation for the biotechnology industry.
The Prohost Letter has been in circulation since 1992. Our readers are comprised of venture capital, fund managers, investors, medical professionals and individuals with one common interest, biotechnology.
Prohost Letter is posted in the members areas on the www.prohostbiotech.com. around 40 times a year. Articles are posted several times a week for subscribers in TODAY'S HIGHLIGHTS section and in News & Comments sector for all website visitors
James Altucher was the managing director of Formula Capital, an asset management firm and fund of hedge funds. He's written five books on investing: Trade Like a Hedge Fund, Trade Like Warren Buffett, SuperCash, The Forever Portfolio, and his latest book, The Choose Yourself Guide To Wealth. He currently writes at Jamesaltucher.com and has released a newsletter, The Altucher Report.
Mr. Altucher is the founder of Stockpickr.com, a social network for finance that had millions of unique visitors per month when it was sold to TheStreet.com in 2007. He has written over 200 columns for The Financial Times and has written for TheStreet.com, Forbes, Yahoo Finance, Fidelity.com, and other publications. He was also the founder of a web services firm, Reset Inc, which he sold in 1998, at which time he became a partner at VC firm, 212 Ventures/Investcorp. Mr. Altucher regularly appears on CNBC, Fox News, Fox Business, and CNN Radio, and is also in his spare time a nationally ranked chess master. Mr. Altucher received his BA at Cornell University and attended graduate school for computer science at Carnegie Mellon University.
You can follow him on twitter @jaltucher.
Douglas Cress is the former editor-in-chief of OneMedPlace (http://www.onemedplace.com/blog), a research firm focused on emerging healthcare and life sciences companies. He led conception and production of the company's publications, Med Tech Sentinel and Medical Technology Investment Digest from 2006 to 2008. Cress graduated with highest honors from Tufts University in 2004.
John received his PhD in chemistry in the research group of Nobel Laureate Donald Cram in 1987 and his MBA from the Anderson School of Management at UCLA in 2009. His research career spans 16 years performing drug discovery research in metabolic diseases, cancer, HIV infection, antibacterials, and Alzheimer's disease. In 2011 John joined Sagient Research Systems as a Biotechnology Analyst. In 2013 he joined Zack's Small Cap Research as an Analyst.
On Twitter: @johntuckerphd
As John is neither licensed nor qualified to act as an investment advisor, his articles are written for discussion purposes only and should not be construed as investment advice. He makes a reasonable effort to avoid misstatements of fact, but advises all investors to consult primary sources prior to making an investment.
Mr. Becker has more than 15-years of experience as a serial entrepreneur, C-level industry executive, drug developer, Wall Street securities analyst and registered financial advisor. He is also an online communications pioneer, popular blogger, and a sought-after speaker at industry events.
Before establishing MD Becker Partners LLC (www.mdbpartners.com) in 2008, he served as president, chief executive officer, and member of the Board of Directors for several publicly-traded biotechnology companies including commercial-stage Cytogen Corporation (acquired by EUSA Pharma) and development-stage VioQuest Pharmaceuticals, Inc.
While at Cytogen, Mr. Becker held positions of increasing responsibility, including Vice President of Business Development, Industry Relations, Investor Relations and Chief Executive Officer of AxCell Biosciences, a subsidiary of Cytogen focused on signal transduction pathways. During his tenure at Cytogen, Mr. Becker raised in excess of $130 million in new capital through both public offerings and private placements and in-licensed Caphosol(c), a topical oral agent and prescription medical device for the treatment of oral mucositis and xerostomia.
Prior to joining Cytogen, Mr. Becker was with Wayne Hummer Investments LLC, a Chicago-based regional brokerage firm, where he held senior positions as a biotechnology securities analyst, financial advisor and portfolio manager. He was also the founder and Executive Editor of Beck on Biotech, a monthly biotechnology investment newsletter published from July 1998 through March 2001. Mr. Becker was previously with Kidder, Peabody & Co., Gruntal & Co., L.L.C., and Kemper Securities. He has previously held the following financial licenses: Series 7 (Registered Representative), Series 16 (Securities Analyst), Series 63 (Uniform Securities Agent) and Series 65 (Registered Investment Advisor).
Mr. Becker plays an active leadership role as an advocate for the biotechnology industry. He is past Chairman and member of the board of trustees with BioNJ, which is New Jersey's trade association for biotechnology companies, and is currently a member of BioNJ, Pennsylvania Bio, the New Jersey Technology Council (NJTC), and the Pharmaceutical Consulting Consortium, Inc. (PCCI). Mr. Becker placed as a biotechnology/life sciences finalist for the Ernst & Young Entrepreneur of the Year award in both 2004 and 2005 and was listed in BusinessWeek's "CEO's 40 and Under" article in December 2006. He attended DePaul University in Chicago, Illinois.
MD Becker Partners newsletter site can be found at: http://lifesciencedigest.com
Joe is a little bit of an oddity, purchasing his first stock (Eastern Airline) at the age of eleven after a family trip. Thirty years later his focus is now Biotech and searching out the next market shakers. Acknowledging his lack of scientific skills, Joe uses technical analysis to signal major Biotech moves and then searches for the reason. If no near term catalyst is found to move the stock it is abandoned for a better choice.
The founding members of Chimera Research Group have over 50 years of combined experience in the biotech and pharmaceutical sector. Their experience includes work at Investment Banks, Hedge Funds, Pharmaceutical Companies, top-tier Universities, and the U.S. Food and Drug Administration (FDA). Their published work includes freelance and editorial contributions both print and on-line, clinical and medical research, books and tutorials, as well as contributions to on-line social media. Through these and other activities they were able to collaborate and connect amongst themselves to establish this cadre of like-minded biotech/pharma trading and investing aficionados.
The Team includes:
Chief Scientific Analyst - Jason Chew
Chief Research Analyst - Patrick Crutcher
Chief Medical Analyst - Dr. Tro Kalayjian
CEO & Trading Analyst - Tony Pelz
Research Analyst - Dr. Andrew Goodwin
Research Analyst - Dr. Juan Pedro Rodríguez Serrate
Technical Analyst - Joe Gantoss
Research Analyst - Dr. Steven Murphy
I am an attorney in Baltimore, Md., representing children with lead poisoning. I have been investing in biotech for over a decade.
I have an A.B. from Vassar College '76, Phi Beta Kappa; J.D. from Duke Law School '79; M.S. from Johns Hopkins University '08.
M.E. Garza is one of the founders of the biotech and healthcare sector news portal BioMedReports.com. He believes in getting the news from credible sources on the street and often reaches out to CEOs and newsmakers directly for interviews and discussions about their companies. Since he began publishing in 2008, Garza has built a reputation as a writer and reporter who can move markets. His track record for accurately reporting rumors and alerting readers about developments in the biotech/healthcare sector is unmatched during that time.
The Burrill Report is written for everyone who wants to understand how biotechnology operates as a business. Each month the publication focuses on the health of the industry and the strategies that will be needed to be successful. It provides actionable market intelligence on the latest global developments and trends in the life sciences industry. Available monthly, subscribers also benefit from monthly and quarterly market financial and business statistics on:
- Public companies
- venture financings
- Project Runway – Follow the global life sciences companies filing for and completing their IPOs – and their post market performances
- Clinical Trials successes and failures
- M&A and Partnering deals
- Periodic country features on Canada, Europe and emerging countries such as China & India.
In addition, BR provides in-depth coverage on specific sectors of life sciences including: Personalized Medicine; Diagnostics, Medical Devices and Biogreentech (Ag-Bio and Biofuels/Bioenergy). Through weekly Burrill Indices, the progress and prospects of biotech companies by size, from small through to blue-chip are also tracked.
Visit: The Burrill Report to obtain your sample issue (http://www.burrillreport.com/)